Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease

ZED1227 is a small molecule tissue transglutaminase (TG2) inhibitor. The compound selectively binds to the active state of TG2, forming a stable covalent bond with the cysteine in its catalytic center. The molecule was designed for the treatment of celiac disease. Celiac disease is an autoimmune-med...

Descripción completa

Detalles Bibliográficos
Autores principales: Büchold, Christian, Hils, Martin, Gerlach, Uwe, Weber, Johannes, Pelzer, Christiane, Heil, Andreas, Aeschlimann, Daniel, Pasternack, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139979/
https://www.ncbi.nlm.nih.gov/pubmed/35626704
http://dx.doi.org/10.3390/cells11101667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139979/
https://www.ncbi.nlm.nih.gov/pubmed/35626704
http://dx.doi.org/10.3390/cells11101667

Ejemplares similares